Carlos Barrios and Pablo Mando
May 15, 2025, 14:51
Pablo Mando: T-DXd demonstrated benefit over Capecitabine and Taxane in HR+/HER2- MBC
Pablo Mando, Editor-in-Chief of Oncologia Clínica, shared a post on X:
“Great presentation by Carlos Barrios reporting that T-DXd demonstrated a clinically meaningful efficacy benefit over both TPC subgroups (capecitabine and taxane), with improved PFS, ORR, DOR, and PFS2 in DB-06.”
Paolo Tarantino, Advanced Research Fellowship at Dana-Farber Cancer Institute and Harvard Medical School, reshared the post on X, adding:
“Seems to confirm a frequent empirical finding:
capecitabine > taxanes for treating HR+/HER2- MBC (with T-DXd outperforming both).”
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41